Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Segment Reporting Information [Line Items]
Revenues	[1]	$ 25,661	$ 14,516
Income from continuing operations before provision/(benefit) for taxes on income	[2]	9,050	5,692
Net gains/(losses) recognized during the period on equity securities	[3],[4]	(699)	401
ViiV [Member]
Segment Reporting Information [Line Items]
Dividend income		56	27
Other Business Activities [Member]
Segment Reporting Information [Line Items]
Revenues	[5]	338	391
Income from continuing operations before provision/(benefit) for taxes on income	[2],[5]	(2,475)	(2,048)
Reconciling Items [Member] | Amortization of Intangible Assets [Member]
Segment Reporting Information [Line Items]
Revenues		0	0
Income from continuing operations before provision/(benefit) for taxes on income	[2]	(835)	(870)
Reconciling Items [Member] | Acquisition-Related Items [Member]
Segment Reporting Information [Line Items]
Revenues		0	0
Income from continuing operations before provision/(benefit) for taxes on income	[2]	(187)	61
Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Revenues	[6]	0	0
Income from continuing operations before provision/(benefit) for taxes on income	[2],[6]	(891)	166
Net gains/(losses) recognized during the period on equity securities		(698)	399
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues	[1],[7]	25,323	14,125
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		25,323	14,125
Income from continuing operations before provision/(benefit) for taxes on income	[2]	$ 13,438	$ 8,383

[1] On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See Note 1A.

[2] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $56 million in the first quarter of 2022 and $27 million in the first quarter of 2021.

[3] Reported in Other (income)/deductions––net. See Note 4.

[4] The losses in the first quarter of 2022 include, among other things, unrealized losses of $473 million related to our investment in BioNTech. The gains in the first quarter of 2021 included, among other things, unrealized gains of $409 million related to investments in Allogene Therapeutics, Inc. and BioNTech.

[5] Other business activities include revenues and costs associated with PC1, as well as costs that we do not allocate to our operating segments, per above.

[6] Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). For earnings in the first quarter of 2022, includes, among other items, net losses on equity securities of $698 million recorded in Other (income)/deductions––net. For earnings in the first quarter of 2021, includes, among other items, net gains on equity securities of $399 million recorded in Other (income)/deductions––net.

[7] At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($47 million for the first quarter of 2022), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure.